Skip to main content
Premium Trial:

Request an Annual Quote

Ramot at Tel-Aviv University, Nanogen, Becton Dickinson Partnership, Fuji Photo Film, Northwest Biotherapeutics

Premium

Ramot at Tel-Aviv University of Tel Aviv, Israel has received US Patent No. 6,865,491, “Method for sequencing polynucleotides” The patent covers a method for obtaining a nucleotide sequence that is indicative of the sequence of a target polynucleotide molecule T. The method makes use of hybridization data obtained by incubating T with nucleotide probes. A score is assigned to each of a plurality of candidate nucleotide sequences based upon the hybridization data and upon at least one reference nucleotide sequence. A candidate nucleotide sequence in then selected having an essentially maximal score.


Nanogen and Becton Dickinson Partnership of San Diego, Calif., have received US Patent No. 6,864,071, “Multiplex amplification and separation of nucleic acid sequences using ligation-dependant strand displacement amplification in bioelectronic chip technology.” The patented invention relates broadly to devices, methods, and compositions of matter for the multiplex amplification, detection and analysis of nucleic acid sequences wherein the amplification, detection and analysis is optimally accomplished using SDA in combination with bioelectronic microchip technology. The invention provides various efficient and optimal methods of amplifying target nucleic acids of interest as well as methods for analyzing resultant amplicons. In addition, the invention enables the amplification and analysis (either sequentially or simultaneously) of multiple samples containing target nucleic acids on a single open bioelectronic microchip.


Fuji Photo Film of Kanagawa, Japan, has received US Patent No. 6,864,055, “Method for detecting nucleic acids.” The patent covers a method of detecting nucleic acid fragments in plural samples is performed by the steps of: attaching an electroconductive label to nucleic acid fragments in one sample and attaching a different electroconductive label to nucleic acid fragments in another sample; preparing a mixture of these samples; spotting the mixture on an electroconductive microarray having plural electrodes onto which probe molecules complementary to the nucleic acid fragments are fixed, so that hybridization between the nucleic acid fragments and the probe molecules on the electroconductive microarray can proceed to form hybrid structures; applying to the electrode an electric potential corresponding to the oxidation-reduction potential of the former label and detecting on the electrode an electric current; applying to the electrode an electric potential corresponding to the oxidation-reduction potential of the latter label and detecting on the electrode an electric current; and comparing the electric current detected in the former detecting procedure and that detected in the latter detecting procedure.


Northwest Biotherapeutics of Bothell, Wash. has received US Patent No. 6,863,887, “Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis.” The patented invention relates to the discovery of a novel role for CXCR-4 in the aberrant proliferative behavior of a number of cell types, including numerous primary tumors and derived cell lines. In particular, patented invention relates to the identification of the role of CXCR-4 in cell transformation and tumorigenesis, in particular, brain, breast and colon tumors. It encompasses therapeutic and diagnostic applications based on CXCR-4 proteins, nucleic acids, and agonists and antagonists, for the treatment or prevention of tumorigenesis as well as screening assays for and therapeutic and diagnostic applications based on a ligand of CXCR-4, SDF-1 and SPF-1 proteins, nucleic acids, and agonists and antagonists, for the treatment or prevention of tumorigenesis.

 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.